US-based biopharmaceutical company Celladon closed a $43 equity round on Wednesday led by Pfizer Ventures, the corporate venturing fund for pharmaceutical corporation Pfizer. Two other corporate venturing funds for pharma companies – Novartis Venture Funds, and Johnson & Johnson Development Corporation – also participated in the round, as did life science venture funds Hambrecht &…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
